osteoarthritis

MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award

MEDIPOST’s treatment for knee osteoarthritis, enters phase 3 clinical trials in Japan

MEDIPOST speeds up its global commercialization of CARTISTEM by requesting official product approval in Malaysia

MEDIPOST receives approval for processing the phase 3 clinical trial of CARTISTEM in Japan

MEDIPOST Clears Phase II Clinical Trial Approval for CARTISTEM in Japan

MEDIPOST Receives Approval for Phase III Clinical Trial of CARTISTEM for the Treatment of Osteochondral Cartilage Defects in Ankle Joint

MEDIPOST to Expand the GMP facility to increase manufacturing capacity for CARTISTEM and new pipeline of products

MEDIPOST Treats First Patient with Injectable Cell Therapeutic for Knee Osteoarthritis

MEDIPOST’s Injectable Cell Therapeutic for Knee Osteoarthritis Receives Phase 1 Clinical Trial Approval

MEDIPOST, announces the clinical trial achievements at Bio USA

MEDIPOST, announces a domestic and international clinical experience at the ISCT annual meeting

MEDIPOST, hits a record high in 1Q sales…Operating profits turn around